LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

Search

Regeneron Pharmaceuticals Inc

Geschlossen

BrancheGesundheitswesen

556.3 -0.37

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

554.37

Max

562.13

Schlüsselkennzahlen

By Trading Economics

Einkommen

583M

1.4B

Verkäufe

647M

3.7B

KGV

Branchendurchschnitt

14.063

35.733

EPS

8.22

Dividendenrendite

0.31

Gewinnspanne

37.86

Angestellte

15,182

EBITDA

617M

1.7B

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+32.5% upside

Dividenden

By Dow Jones

Dividendenrendite

Branchendurchschnitt

0.31%

3.13%

Nächstes Ergebnis

30. Okt. 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-1.1B

59B

Vorheriger Eröffnungskurs

556.67

Vorheriger Schlusskurs

556.3

Nachrichtenstimmung

By Acuity

40%

60%

122 / 371 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Very Strong Bearish Evidence

Regeneron Pharmaceuticals Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

1. Aug. 2025, 11:33 UTC

Ergebnisse

Regeneron 2Q Revenue, Adjusted EPS Top Estimates

1. Aug. 2025, 13:16 UTC

Ergebnisse

Regeneron Stock Is Rising on Earnings. This Sanofi Collaboration Is Helping. -- Barrons.com

1. Aug. 2025, 12:40 UTC

Ergebnisse

Regeneron Stock Is Rising on Earnings. This Sanofi Collaboration Is Helping. -- Barrons.com

1. Aug. 2025, 10:41 UTC

Ergebnisse

Regeneron Now Sees 2025 Adjusted R&D $5.1B-$5.2B; Had Seen $5B-$5.2B >REGN

1. Aug. 2025, 10:41 UTC

Ergebnisse

Regeneron Now Sees 2025 Capital Spending $880M-$950M; Had Seen $850M-$950M >REGN

1. Aug. 2025, 10:40 UTC

Ergebnisse

Regeneron Now Sees 2025 Adjusted Gross Margin on Net Product Sales About 86%; Had Seen 86%-87% >REGN

1. Aug. 2025, 10:38 UTC

Ergebnisse

Regeneron: Odronextamab Application Also Impacted by Site Inspection >REGN

1. Aug. 2025, 10:37 UTC

Ergebnisse

Regeneron Gets FDA Complete Response Letter for Odronextamab in Follicular Lymphoma >REGN

1. Aug. 2025, 10:35 UTC

Ergebnisse

Regeneron: Anticipate Expeditious Resolution of Filling Issues for Eylea HD >REGN

1. Aug. 2025, 10:34 UTC

Ergebnisse

Regeneron Cites Observations From FDA General Site Inspection at Filler for Eylea HD >REGN

1. Aug. 2025, 10:33 UTC

Ergebnisse

Regeneron Sees FDA Approvals Delayed for Eylea HD Indications With August Target Actio Dates >REGN

1. Aug. 2025, 10:32 UTC

Ergebnisse

Regeneron Pharma: About 45 Product Candidates in Clinical Development >REGN

1. Aug. 2025, 10:31 UTC

Ergebnisse

Regeneron Pharma 2Q Eylea HD, Eylea U.S. Net Sales Fell 25% to $1.15B >REGN

1. Aug. 2025, 10:31 UTC

Ergebnisse

Regeneron Pharma: 2Q Dupixent Global Net Sales Recorded by Sanofi Rose 22% to $4.34B >REGN

1. Aug. 2025, 10:30 UTC

Ergebnisse

Regeneron Pharma 2Q Adj EPS $12.89 >REGN

1. Aug. 2025, 10:30 UTC

Ergebnisse

Regeneron Pharma 2Q Rev $3.68B >REGN

1. Aug. 2025, 10:30 UTC

Ergebnisse

Regeneron Pharma 2Q EPS $12.81 >REGN

1. Aug. 2025, 10:30 UTC

Ergebnisse

Regeneron Pharma 2Q Net $1.39B >REGN

13. Juni 2025, 21:42 UTC

Akquisitionen, Fusionen, Übernahmen

Anne Wojcicki Wins Bidding for 23andMe -- 2nd Update

13. Juni 2025, 20:45 UTC

Akquisitionen, Fusionen, Übernahmen

23andMe: TTAM Makes Binding Commitments for Additional Consumer Protections and Privacy Safeguards

13. Juni 2025, 20:34 UTC

Akquisitionen, Fusionen, Übernahmen

Anne Wojcicki Wins Bidding for 23andMe -- Update

13. Juni 2025, 20:14 UTC

Akquisitionen, Fusionen, Übernahmen

Nonprofit Controlled By 23andMe Co-Founder Anne Wojcicki Would Buy the DNA-Testing Company for $305 Million -- WSJ

13. Juni 2025, 20:14 UTC

Akquisitionen, Fusionen, Übernahmen

Anne Wojcicki Wins Bidding for 23andMe -- WSJ

13. Juni 2025, 20:14 UTC

Akquisitionen, Fusionen, Übernahmen

Regeneron Walks Away From 23andMe Acquisition After Wojcicki's Higher Bid -- WSJ

5. Juni 2025, 01:41 UTC

Akquisitionen, Fusionen, Übernahmen

23andMe's Former CEO Pushes Purchase Price Nearly $50 Million Higher -- WSJ

30. Mai 2025, 08:58 UTC

Heiße Aktien

Stocks to Watch Friday: Dell, Marvell, Gap, Ulta -- WSJ

30. Mai 2025, 08:56 UTC

Market Talk

Sanofi, Regeneron Hit by Trial Disappointment -- Market Talk

19. Mai 2025, 17:52 UTC

Top News
Akquisitionen, Fusionen, Übernahmen

Regeneron to Buy 23andMe Out of Bankruptcy for $256 Million -- 2nd Update

19. Mai 2025, 16:13 UTC

Akquisitionen, Fusionen, Übernahmen

Regeneron Is Buying 23andMe. The Deal Is a Head Scratcher. -- Barrons.com

19. Mai 2025, 14:42 UTC

Top News
Akquisitionen, Fusionen, Übernahmen

Regeneron to Buy 23andMe Out of Bankruptcy for $256 Million -- 2nd Update

Peer-Vergleich

Kursveränderung

Regeneron Pharmaceuticals Inc Prognose

Kursziel

By TipRanks

32.5% Vorteil

12-Monats-Prognose

Durchschnitt 739.95 USD  32.5%

Hoch 890 USD

Tief 543 USD

Basierend auf 22 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Regeneron Pharmaceuticals Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

22 ratings

17

Buy

4

Halten

1

Sell

Technischer Score

By Trading Central

542.44 / 599.76Unterstützung & Widerstand

Kurzfristig

Very Strong Bearish Evidence

Mittelfristig

Strong Bullish Evidence

Langfristig

Weak Bearish Evidence

Stimmung

By Acuity

122 / 371 Ranking in Gesundheitswesen

Nachrichtenstimmung

Bullische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Überdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types; and with Sonoma Biotherapeutics, Inc. to discover, develop, and commercialize engineered regulatory T cell therapies. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.
help-icon Live chat